Clinical Trial Update: A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating bevacizumab in combination with rituximab and CHOP for diffuse large B-cell lymphoma was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: B-cell Lymphoma | Phase 3 | Status: TERMINATED | Results posted: 2012-12-31